Open AccessImpact of apolipoprotein E genotypes on vitamin E and memantine treatment outcomes in Alzheimer's disease
Author(s) -
BelitskayaLévy Ilana,
Dysken Maurice,
Guarino Peter,
Sano Mary,
Asthana Sanjay,
Vertrees Julia E.,
Pallaki Muralidhar,
Llorente Maria,
Love Susan,
Schellenberg Gerard
Publication year - 2018
Publication title -
alzheimer's and dementia: translational research and clinical interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.49
H-Index - 30
ISSN - 2352-8737
DOI - 10.1016/j.trci.2018.06.001
Subject(s) - memantine , apolipoprotein e , medicine , placebo , randomized controlled trial , genotype , vitamin e , galantamine , disease , alzheimer's disease , oncology , dementia , biology , donepezil , pathology , genetics , biochemistry , alternative medicine , gene , antioxidant
Because apolipoprotein E (APOE) genotypes are known risk factors for Alzheimer's disease (AD), they have been measured in clinical trial participants to determine their effect on treatment outcome. Methods We determined APOE genotypes in a subset of subjects (N = 415) who participated in a randomized controlled trial of vitamin E and memantine in 613 veterans with mild‐to‐moderate AD. Results Similar to the primary study, substudy participants receiving vitamin E also had slower functional decline than those receiving placebo. Overall, there was no difference in the rate of functional decline between APOE ε4 allele carriers and noncarriers. A significant interaction was observed between treatment and the APOE genotype on AD progression: ε4 carriers declined faster than noncarriers in the vitamin E plus memantine treatment arm. Discussion APOE genotypes may modulate AD treatment response and should be included in the design of future randomized controlled trials.